Details

Autor(en) / Beteiligte

• Burkes, Robert M.
• Ceppe, Agathe S.
• Doerschuk, Claire M.
• Couper, David
• Hoffman, Eric A.
• Comellas, Alejandro P.
• Barr, R. Graham
• Krishnan, Jerry A.
• Cooper, Christopher
• Labaki, Wassim W.
• Ortega, Victor E.
• Wells, J. Michael
• Criner, Gerard J.
• Woodruff, Prescott G.
• Bowler, Russell P.
• Pirozzi, Cheryl S.
• Hansel, Nadia N.
• Wise, Robert A.
• Brown, Todd T.
• Drummond, M. Bradley
• Alexis, Neil E.
• Anderson, Wayne H.
• Arjomandi, Mehrdad
• Barjaktarevic, Igor
• Bateman, Lori A.
• Bhatt, Surya P.
• Bleecker, Eugene R.
• Boucher, Richard C.
• Christenson, Stephanie A.
• Cooper, Christopher B.
• Couper, David J.
• Crystal, Ronald G.
• Curtis, Jeffrey L.
• Dransfield, Mark T.
• Drummond, Brad
• Freeman, Christine M.
• Galban, Craig
• Han, MeiLan K.
• Hastie, Annette T.
• Huang, Yvonne
• Kaner, Robert J.
• Kanner, Richard E.
• Kleerup, Eric C.
• LaVange, Lisa M.
• Lazarus, Stephen C.
• Martinez, Fernando J.
• Meyers, Deborah A.
• Moore, Wendy C.
• Newell, John D.
• Paine, Robert
• Paulin, Laura
• Peters, Stephen P.
• Pirozzi, Cheryl
• Putcha, Nirupama
• Oelsner, Elizabeth C.
• O’Neal, Wanda K.
• Raman, Sanjeev
• Rennard, Stephen I.
• Tashkin, Donald P.
• Postow, Lisa
• Viviano, Lisa

Titel

Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD

Ist Teil von

• Chest, 2020-04, Vol.157 (4), p.856-865

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The relationship between 25-hydroxyvitamin D (25-OH-vitamin D) and COPD outcomes remains unclear. Using the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), we determined associations among baseline 25-OH-vitamin D and cross-sectional and longitudinal lung function and COPD exacerbations. Serum 25-OH-vitamin D level was measured in stored samples from 1,609 SPIROMICS participants with COPD. 25-OH-vitamin D levels were modeled continuously and dichotomized as deficient (< 20 ng/mL) vs not deficient (≥ 20 ng/mL). Outcomes of interest included % predicted FEV1 (current and 1-year longitudinal decline) and COPD exacerbations (separately any and severe, occurring in prior year and first year of follow-up). Vitamin D deficiency was present in 21% of the cohort and was more prevalent in the younger, active smokers, and blacks. Vitamin D deficiency was independently associated with lower % predicted FEV1 (by 4.11%) at enrollment (95% CI, –6.90% to –1.34% predicted FEV1; P = .004), 1.27% predicted greater rate of FEV1 decline after 1 year (95% CI, –2.32% to –0.22% predicted/y; P = .02), and higher odds of any COPD exacerbation in the prior year (OR, 1.32; 95% CI, 1.00-1.74; P = .049). Each 10-ng/mL decrease in 25-OH-vitamin D was associated with lower baseline lung function (–1.04% predicted; 95% CI, –1.96% to –0.12% predicted; P = .03) and increased odds of any exacerbation in the year before enrollment (OR, 1.11; 95% CI, 1.01-1.22; P = .04). Vitamin D deficiency is associated with worse cross-sectional and longitudinal lung function and increased odds of prior COPD exacerbations. These findings identify 25-OH-vitamin D levels as a potentially useful marker of adverse COPD-related outcomes.